The defense prime contractors have a new problem on their hands

US Army Secretary Dan Driscoll said the military needed to "completely disrupt the system" that "lined the primes' pockets ...

LUCA INTERSECTS HIGH-GRADE GOLD AT REFORMA, INCLUDING 13 METRES OF 11.4 GRAMS PER TONNE GOLD EQUIVALENT

Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) is pleased to report analytical results from four additional surface drillholes at the Reforma deposit and two ...
Medical Marketing & Media

Pipeline Report 2025: Late-stage programs set to reshape treatment

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Denny Hamlin seizes Las Vegas victory to clinch Championship 4 berth

Four fresh tires proved to be the winning hand for Denny Hamlin, with the No. 11 Joe Gibbs Toyota winning the Cup Series ...
Targeted Oncology

T-Cell Engager Toxicities in Solid Tumors: Recognition and Management

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Le Lézard

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

Gilead Sciences, Inc. and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 ...